Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | STAT6 | P42226 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | NTSR1 | P30989 | 6/20 | 0.35 |
| ▸ | WHR1 | P49842 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30045784 | 1.00 | PDE9A (0.41) | PDE9ASMN1; SMN2ALDH1A1KDM4ESTAT6 | |
| SCHEMBL29577755 | 0.94 | PDE9A (0.38) | PDE9ASMN1; SMN2ALDH1A1KDM4ESTAT6 | |
| SCHEMBL20331739 | 0.94 | PDE9A (0.38) | PDE9ASMN1; SMN2ALDH1A1KDM4ESTAT6 | |
| SCHEMBL30044646 | 0.90 | PDE9A (0.40) | PDE9ASMN1; SMN2ALDH1A1KDM4ESTAT6 | |
| SCHEMBL21240381 | 0.90 | PDE9A (0.40) | PDE9ASMN1; SMN2ALDH1A1KDM4ESTAT6 | |
| SCHEMBL21251799 | 0.90 | PIK3CA (0.36) | PDE9ASMN1; SMN2ALDH1A1KDM4ESTAT6 | |
| SCHEMBL20332261 | 0.90 | PDE10A (0.41) | SMN1; SMN2ALDH1A1KDM4ESTAT6NPSR1 | |
| SCHEMBL29578517 | 0.90 | PDE10A (0.41) | SMN1; SMN2ALDH1A1KDM4ESTAT6NPSR1 | |
| SCHEMBL20331490 | 0.90 | SMN1; SMN2 (0.34) | PDE9ASMN1; SMN2ALDH1A1KDM4ESTAT6 | |
| SCHEMBL29577390 | 0.90 | SMN1; SMN2 (0.34) | PDE9ASMN1; SMN2ALDH1A1KDM4ESTAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11555036-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-01-17 | — | — | US | disclosed |
| EP-3524603-B1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2022-06-08 | — | — | EP | disclosed |
| US-10968220-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| US-10968220-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| US-20190270742-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2019-09-05 | — | — | US | disclosed |
| US-20190270742-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2019-09-05 | — | — | US | disclosed |
| EP-3524603-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2019-08-14 | — | — | EP | disclosed |
| EP-3524603-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2019-08-14 | — | — | EP | disclosed |
| WO-2018113584-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 上海和誉生物医药科技有限公司 | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270742-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | FGFR4, FGFR2, FGFR1 | PDE9A 4178/4885SMN1; SMN2 1556/4885ALDH1A1 927/4885 |
| US-11555036-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | FGFR4, FGFR2, FGFR1 | PDE9A 4178/4885SMN1; SMN2 1556/4885ALDH1A1 927/4885 |
| US-10968220-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | FGFR4, FGFR2, FGFR1 | PDE9A 4178/4885SMN1; SMN2 1556/4885ALDH1A1 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.